If you held stock in Exact Sciences on May 17, chances are you went to bed happy on May 18. It was on May 18 that a U.S. government taskforce officially announced a change in its guidelines for … [Read more...]
Increasing Revenue
New Colorectal Cancer Screening Guidelines Are a Windfall for Exact Sciences, Cologuard
June 8, 2021
Inside the Lab Industry
COVID-19 Surge Lifts Overall Molecular Point of Care Testing Market to $900 Million
April 3, 2021
To the uninitiated, the term molecular point-of-care (POC) testing might sound like an oxymoron. After all, the science of molecular microbiology is all about detecting targeted bits of microbial … [Read more...]
Industry Buzz
Guardant Health Challenges Exact Sciences’ Leadership of Colorectal Cancer Diagnostics Market
February 26, 2021
Colorectal cancer diagnostics is a multi-billion-dollar market that, at least before the pandemic, was projected to grow at an annual rate of nearly 6 percent. In recent months, two leading firms have … [Read more...]
Industry Buzz
Myriad Genetics Puts Its Autoimmune Division Up for Sale
January 30, 2021
What a difference a pandemic makes! Last year at this time, molecular genetic testing was a fairly soft market. But the unprecedented and unexpected demand for COVID-19 diagnostics has lifted the … [Read more...]
Inside the Lab Industry
Equity Fund Acquires Controlling Stake in Ancestry.com as Demand for At-Home Genetic Testing Fades
November 2, 2020
Many believe that the boom for direct to consumer genetic testing had passed even before the pandemic began. Still, the sector is abuzz with strategic activity. In August, private equity firm … [Read more...]
Market Trends
COVID-19 Fuels Massive & Sustainable Growth in Molecular Diagnostics
August 7, 2020
While it may be decimating demand for most lab tests, COVID-19 is driving incredible growth in molecular testing. The global market for molecular diagnostics will top $13 billion in 2020, about $5 … [Read more...]
REIMBURSEMENT
Genetic Testing: New Medicare Early NGS Cancer Test Coverage Policy Is Less than Meets the Eye
January 3, 2020
For Myriad Genetics, Foundation Medicine and other manufacturers of next-generation sequencing (NGS)-based test panels for early-stage cancer risk assessment, the recent announcement of CMS’ decision … [Read more...]
INDUSTRY BUZZ
Google This: Labs Partner with Tech Giant
July 28, 2019
In recent months, several diagnostic companies have announced alliances with Google, and all involve Google Cloud Platform. Here is how four companies are using Google's … [Read more...]
REIMBURSEMENT
Medicare Reimbursement: CMS Limits NGS Early Cancer Test Coverage but Industry Fires Back
February 22, 2019
Getting Medicare to cover Next Generation Sequencing (NGS) tests has been a slow go. And the latest CMS National Coverage Determination (NCD) for early stage cancer NGS testing of patients with … [Read more...]
ACCREDITATION
Top of the News: ANDE Rapid DNA Platform First to Win FBI Approval
June 25, 2018
"Great news! The FBI just called." --Extremely rare phrase almost never uttered except sarcastically One of the very few exceptions to the above principle is ANDE (previously known as NetBio), a … [Read more...]
